NYR.AX · NYRADA INC.
Australia · RS rating 31 · As of 2026-10-14
| Price | 0.48 AUD |
|---|---|
| 1-day change | +4.3% |
| RS rating (overall / 1M / 3M / 12M) | 31 / 4 / 42 / 85 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 29 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (–) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +65.2% |
| Market cap (USD) | $86.4M |